BioCEP

Company Overview

Snapshot

Founded in July 2006, BioCEP operated with 1–10 employees and raised $6.83 million across two funding rounds from three investors. The company ceased operations in September 2021.

Business overview

BioCEP develops, manufactures, and sells technologies for cell isolation, primarily serving the Health Tech & Life Sciences sector. Its core product, the patented Cell Enrichment Process for Isolation of Rare Cells (CEPir) device, enables immunomagnetic cell isolation for research and development, offering high purity and recovery rates for rare cells. The company also developed applications in noninvasive prenatal testing and stem cell separation, targeting laboratories and biotechnology markets globally.

Company Intelligence Q&A

What is BioCEP's primary technology?

BioCEP's primary technology is the patented Cell Enrichment Process for Isolation of Rare Cells (CEPir) device, which enables effective immunomagnetic cell isolation for research and development purposes.

When did BioCEP cease operations?

BioCEP ceased to operate in September 2021.

What was BioCEP's total capital raised?

BioCEP raised a total of $6.83 million across its funding rounds.

What certifications did BioCEP hold?

BioCEP was certified according to ISO 13485.